Specific gene suppression using antisense strategy for growth suppression of glioma.
Matsuno
Akira
A
Department of Neurosurgery, Teikyo University Ichihara Hospital, 3426-3 Anegasaki, Ichihara, Chiba 299-0111, Japan.
Nagashima
Tadashi
T
D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics; D002455:Cell Division / Q000187:drug effects*; D005910:Glioma / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000235:genetics* / Q000494:pharmacology; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism; D051496:Receptor, Fibroblast Growth Factor, Type 1; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism; D019098:Telomerase / Q000378:metabolism; D016211:Transforming Growth Factor alpha / Q000378:metabolism; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D016376:Oligonucleotides, Antisense; D017468:Receptors, Fibroblast Growth Factor; D016211:Transforming Growth Factor alpha; D042461:Vascular Endothelial Growth Factor A; C496348:FGFR1 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051496:Receptor, Fibroblast Growth Factor, Type 1; D019098:Telomerase